Takeda Wins Fourth U.S. Suit Alleging It Hid Cancer Risks Of Actos Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical won another favorable ruling from a U.S. jury asked to determine if it hid bladder-cancer risks of its Actos (pioglitazone) diabetes drug, this time in a Las Vegas suit filed by two women who got the disease.